Logo image of MDGL

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

USA - NASDAQ:MDGL - US5588681057 - Common Stock

439.93 USD
-0.82 (-0.19%)
Last: 9/19/2025, 8:00:01 PM
439.93 USD
0 (0%)
After Hours: 9/19/2025, 8:00:01 PM
Fundamental Rating

3

MDGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 541 industry peers in the Biotechnology industry. MDGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MDGL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MDGL has reported negative net income.
MDGL had a negative operating cash flow in the past year.
In the past 5 years MDGL always reported negative net income.
MDGL had a negative operating cash flow in each of the past 5 years.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -27.76%, MDGL is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
MDGL's Return On Equity of -40.50% is fine compared to the rest of the industry. MDGL outperforms 71.30% of its industry peers.
Industry RankSector Rank
ROA -27.76%
ROE -40.5%
ROIC N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

MDGL has a better Gross Margin (96.28%) than 95.19% of its industry peers.
MDGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDGL has more shares outstanding
Compared to 5 years ago, MDGL has more shares outstanding
MDGL has a better debt/assets ratio than last year.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

MDGL has an Altman-Z score of 16.27. This indicates that MDGL is financially healthy and has little risk of bankruptcy at the moment.
MDGL has a better Altman-Z score (16.27) than 90.00% of its industry peers.
MDGL has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
MDGL has a worse Debt to Equity ratio (0.17) than 67.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 16.27
ROIC/WACCN/A
WACC9.65%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 5.11 indicates that MDGL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.11, MDGL is in line with its industry, outperforming 55.93% of the companies in the same industry.
A Quick Ratio of 4.78 indicates that MDGL has no problem at all paying its short term obligations.
MDGL has a Quick ratio of 4.78. This is comparable to the rest of the industry: MDGL outperforms 53.89% of its industry peers.
Industry RankSector Rank
Current Ratio 5.11
Quick Ratio 4.78
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.61% over the past year.
MDGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 3421.98%.
EPS 1Y (TTM)49.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.24%
Revenue 1Y (TTM)3421.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1353.76%

3.2 Future

Based on estimates for the next years, MDGL will show a very strong growth in Earnings Per Share. The EPS will grow by 38.01% on average per year.
Based on estimates for the next years, MDGL will show a very strong growth in Revenue. The Revenue will grow by 84.62% on average per year.
EPS Next Y51.76%
EPS Next 2Y44.56%
EPS Next 3Y42.69%
EPS Next 5Y38.01%
Revenue Next Year400.82%
Revenue Next 2Y182.22%
Revenue Next 3Y127.69%
Revenue Next 5Y84.62%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 -20 40 60 80

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MDGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 221.47 indicates a quite expensive valuation of MDGL.
Based on the Price/Forward Earnings ratio, MDGL is valued cheaper than 86.48% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.86. MDGL is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 221.47
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MDGL does not grow enough to justify the current Price/Earnings ratio.
MDGL's earnings are expected to grow with 42.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.56%
EPS Next 3Y42.69%

More info and screens

0

5. Dividend

5.1 Amount

MDGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (9/19/2025, 8:00:01 PM)

After market: 439.93 0 (0%)

439.93

-0.82 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners98.35%
Inst Owner Change-2.84%
Ins Owners0.99%
Ins Owner Change0.29%
Market Cap9.81B
Analysts82.61
Price Target475.46 (8.08%)
Short Float %19.67%
Short Ratio10.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.12%
Min EPS beat(2)13.46%
Max EPS beat(2)48.79%
EPS beat(4)4
Avg EPS beat(4)32.47%
Min EPS beat(4)13.46%
Max EPS beat(4)48.79%
EPS beat(8)5
Avg EPS beat(8)13.82%
EPS beat(12)6
Avg EPS beat(12)8.91%
EPS beat(16)9
Avg EPS beat(16)7.2%
Revenue beat(2)2
Avg Revenue beat(2)23.38%
Min Revenue beat(2)18.22%
Max Revenue beat(2)28.53%
Revenue beat(4)4
Avg Revenue beat(4)31.95%
Min Revenue beat(4)2.78%
Max Revenue beat(4)78.29%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.78%
PT rev (3m)10.48%
EPS NQ rev (1m)11.38%
EPS NQ rev (3m)33.31%
EPS NY rev (1m)21.21%
EPS NY rev (3m)17.44%
Revenue NQ rev (1m)7.3%
Revenue NQ rev (3m)59.22%
Revenue NY rev (1m)27.56%
Revenue NY rev (3m)27.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 221.47
P/S 19.02
P/FCF N/A
P/OCF N/A
P/B 14.09
P/tB 14.18
EV/EBITDA N/A
EPS(TTM)-12.85
EYN/A
EPS(NY)1.99
Fwd EY0.45%
FCF(TTM)-13.84
FCFYN/A
OCF(TTM)-13.79
OCFYN/A
SpS23.13
BVpS31.22
TBVpS31.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.76%
ROE -40.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.28%
FCFM N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.74%
Cap/Sales 0.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.11
Quick Ratio 4.78
Altman-Z 16.27
F-Score3
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)305.68%
Cap/Depr(5y)207.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.24%
EPS Next Y51.76%
EPS Next 2Y44.56%
EPS Next 3Y42.69%
EPS Next 5Y38.01%
Revenue 1Y (TTM)3421.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1353.76%
Revenue Next Year400.82%
Revenue Next 2Y182.22%
Revenue Next 3Y127.69%
Revenue Next 5Y84.62%
EBIT growth 1Y41.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.21%
EBIT Next 3Y40.7%
EBIT Next 5YN/A
FCF growth 1Y-11.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.99%
OCF growth 3YN/A
OCF growth 5YN/A